Dyadic International Inc (NASDAQ:DYAI) announced Monday that data presented last week at a major medical conference in Portugal demonstrated that its proprietary C1 strain has been successfully glyco-engineered to impart the core human-like G0 glycan structure at high levels.
The G0 glycosylation data was presented by Markku Saloheimo from the VTT Technical Research Centre of Finland Ltd at the annual PEGS Europe Protein & Antibody Engineering Summit in Lisbon on November 21, according to a statement.
Dyadic said the scientific results were outlined in the presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila.’'
"The exceptionally high level of G0 glycans reached through our glycoengineering work with C1 was a very important interim goal in our ongoing C1 research and development program with Dyadic where we expect to develop additional C1 strains capable of producing complex human glycoforms, such as G0F, G2, and G2F,” said Markku Saloheimo, senior principal scientist at VTT.
Ronen Tchelet, Dyadic's chief scientific officer, called the release of the data “a key milestone for our C1 glyco-engineering program" He said that “reaching G0 glycosylation levels of up to 95% has exceeded our initial objective of 90% and is an important breakthrough for our C1 gene expression platform.”
Dyadic CEO Mark Emalfarb added: "These exciting results further support our recent decision to accelerate our C1 glyco-engineering research program which we expect will allow us and our collaborators to apply C1 for broader uses in the development and manufacture of glyco biologics such as Fc-Fusion proteins and monoclonal antibodies.’
Dyadic, based in Jupiter, Florida, leverages its proprietary C1 technology — an industrially proven fungal gene expression technology — to help bring biologic vaccines, enzymes, proteins, biosimilars, and drugs to market faster and at a lower cost.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham